Palisade Bio, Inc. (NASDAQ:PALI) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Palisade Bio, Inc. (NASDAQ:PALI) have been given a consensus recommendation of “Moderate Buy” by the eight analysts that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, six have issued a buy rating and one has given a strong buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $10.20.

PALI has been the subject of a number of research analyst reports. Wall Street Zen raised shares of Palisade Bio from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. HC Wainwright initiated coverage on shares of Palisade Bio in a research note on Thursday, March 26th. They issued a “buy” rating and a $7.00 price target for the company. Wolfe Research initiated coverage on shares of Palisade Bio in a research note on Thursday, April 9th. They issued an “outperform” rating and a $7.00 price target for the company. Finally, Stifel Nicolaus initiated coverage on shares of Palisade Bio in a research note on Wednesday, February 25th. They issued a “buy” rating and a $5.00 price target for the company.

Institutional Trading of Palisade Bio

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Perceptive Advisors LLC bought a new stake in shares of Palisade Bio in the 4th quarter worth approximately $28,318,000. Commodore Capital LP bought a new stake in shares of Palisade Bio in the 4th quarter worth approximately $26,896,000. Janus Henderson Group PLC raised its holdings in shares of Palisade Bio by 1.4% in the 1st quarter. Janus Henderson Group PLC now owns 10,689,452 shares of the company’s stock worth $18,760,000 after purchasing an additional 149,118 shares in the last quarter. Octagon Capital Advisors LP raised its holdings in shares of Palisade Bio by 7.4% in the 1st quarter. Octagon Capital Advisors LP now owns 10,276,317 shares of the company’s stock worth $17,984,000 after purchasing an additional 708,419 shares in the last quarter. Finally, RA Capital Management L.P. bought a new stake in shares of Palisade Bio in the 4th quarter worth approximately $16,742,000. 11.79% of the stock is currently owned by institutional investors.

Palisade Bio Trading Down 9.8%

Shares of NASDAQ:PALI opened at $1.74 on Friday. The company has a 50 day moving average of $2.00 and a 200-day moving average of $1.93. The firm has a market cap of $302.03 million, a P/E ratio of -1.72 and a beta of 1.52. Palisade Bio has a twelve month low of $0.53 and a twelve month high of $2.86.

Palisade Bio (NASDAQ:PALI) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). Equities research analysts forecast that Palisade Bio will post -0.21 EPS for the current year.

About Palisade Bio

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.